- Home
- BLRX
BLRX
BioLineRx Ltd.
as 05-20-2024 3:34pm EST
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
| Founded: | 2003 | Country: | Israel |
| Employees: | 79 | City: | N/A |
| Market Cap: | 51.2M | IPO Year: | 2011 |
| Target Price: | $12.50 | AVG Volume (30 days): | 416.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $2.53 | Next Earning Date: | 05-28-2024 |
| Revenue: | $4,800,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest BioLineRx Ltd. News
BLRX Breaking Stock News: Dive into BLRX Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
PR Newswire
14 days ago
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
PR Newswire
a month ago
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
PR Newswire
a month ago
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
PR Newswire
2 months ago
BioLineRx Announces $6 Million Registered Direct Offering
Insider Monkey
2 months ago
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
Zacks Small Cap Research
2 months ago
BLRX: First Aphexda Sales Recognized
PR Newswire
2 months ago